← Treatments
CHICOVERY

Psoriasis and complex skin diseases

For patients with moderate to severe psoriasis, China may be of interest because of the combination of modern dermatology, newer locally available biologics, phototherapy and specialised dermatological TCM techniques.

Evidence status: Strong conventional options + meaningful integrative adjunct

What is the medical problem?

Psoriasis is a chronic immune-mediated condition. Some patients respond insufficiently to topical therapy, phototherapy or systemic medication, or experience recurrent severe symptoms, difficult-to-treat locations or significant side effects.

Which options are being considered?

  • Dermatological reassessment using PASI, BSA and DLQI
  • modern biologics, including China-developed IL-17A inhibitors such as xeligekimab and vunakizumab when medically appropriate
  • NB-UVB phototherapy
  • fire needle for selected plaque psoriasis as an adjunctive technique
  • integrated TCM dermatology
  • screening for metabolic and inflammatory comorbidities

What could a treatment pathway look like?

Previous medication, disease severity, joint involvement, infection risk and comorbidities are assessed first. Treatment is then selected based on disease activity and previous therapies. In an integrative pathway, skin photographs, PASI/BSA/DLQI scores and relevant laboratory values are recorded in a standardised manner so that improvement can be monitored objectively.

What do we know about effectiveness?

Biologics and NB-UVB have strong evidence. Xeligekimab and vunakizumab are modern Chinese IL-17A treatments supported by clinical trial data. Randomised research on fire needle has reported positive results in plaque psoriasis, but the evidence remains clearly weaker than for modern biologics. Herbal medicine, cupping and combination therapies remain primarily adjunctive options.

Important selection considerations

Psoriasis should not be presented as ‘cured’. Biologic treatment requires infection screening and specialist monitoring. Herbal and needling treatments should be assessed for interactions, skin infection, bleeding risk and quality of delivery.

Medical selection before travel

The options described are not a guarantee of treatment. Availability and suitability depend on diagnosis, indication, evidence level, individual risks and assessment by the treating medical team. Experimental care is identified as such.

Would you like to know whether a pathway could be medically appropriate?

A treatment journey always begins with an assessment of the diagnosis, medical history, previous treatments, medication, risks and the specific treatment objective.

Start medical intake